Ottava robotics launch: What will set it apart?

Research evidence excerpt

Ottava robotics launch: What will set it apart?

Update

August 3, 2026 02:43 PM GMT

Morgan Stanley & Co. LLCMJohnson & Johnson | North America Terence C Flynn, Ph.D.

Equity Analyst

Ottava robotics launch: What Terence.Flynn@morganstanley.comAlexander Yevdokimov, Ph.D. +1 212 761-2230

Research Associate

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

will set it apart? Damien H Kerner

Damien.H.Kerner@morganstanley.com +1 212 761-3829

JNJ hosted a webcast following FDA de novo authorization of the company's

Hailey Horowitz

robotic surgery system, Ottava, and feedback from the Society of Robotic Research Associate

Surgery annual meeting - LINK, and we provide our takeaways below. Hailey.Horowitz@morganstanley.com +1 212 761-5264

Chris Yu, J.D., Ph.D.

Management walked through several points of differentiation, framed the initial Equity Analyst

commercial launch and, notably, reiterated its conviction that Ottava will be a Chris.L.Yu@morganstanley.com +1 212 761-2535

Connor M Massari

financially material program for JNJ by the end of the decade. Ottava represents a Equity Analyst

potential source of upside to our JNJ MedTech estimates. Connor.Massari@morganstanley.com +1 212 761-2417

Morgan Stanley India Company Private Limited+

What's under the hood? Points of differentiation.

Saket Agarwal

Mgmt centered the launch around several differentiators that set Ottava apart from Saket.Agarwal@morganstanley.com +91 22 6995-4012

existing competitors (i.e., Intuitive Surgical's da Vinci, Medtronic's Hugo - both are

not covered) in the space and required the company to pursue a de novo regulatory Johnson & Johnson (JNJ.N, JNJ UN)

pathway rather than a 510(k), reflecting the system’s unique design ( Exhibit 1 ). Major Pharmaceuticals | United States of America